{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzp7bp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzp7bp\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/29\\\/7\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/29\\\/7\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/29\\\/7\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/29\\\/7\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003ETwo-year data from the Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis [ADVANCE; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00906399\u0026amp;atom=%2Fspmdc%2F14%2F29%2F7.atom\u0022\u003ENCT00906399\u003C\/a\u003E; Kieseier BC et al. ECTRIMS 2014 (poster P042)], a study of relapsing-remitting multiple sclerosis (RRMS) in more than 1500 patients, have confirmed the long-term capability of subcutaneously injected peginterferon beta-1a (PEG-IFN-\u03b2-1a) in lessening disability progression.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EDemyelinating Diseases\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENeurology Clinical Trials\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ENeurology\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EDemyelinating Diseases\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENeurology Clinical Trials\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003ETwo-year data from the Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis [ADVANCE; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00906399\u0026amp;atom=%2Fspmdc%2F14%2F29%2F7.atom\u0022\u003ENCT00906399\u003C\/a\u003E; Kieseier BC et al. ECTRIMS 2014 (poster P042)], a study of relapsing-remitting multiple sclerosis (RRMS) in more than 1500 patients, have confirmed the long-term capability of subcutaneously injected peginterferon beta-1a (PEG-IFN-\u03b2-1a) in lessening disability progression. The findings were presented by Bernd C. Kieseier, MD, Heinrich Heine University, D\u00fcsseldorf, Germany.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EThe 1-year data from the placebo-controlled ADVANCE study showed the efficacy of PEG-IFN-\u03b2-1a in reducing relapse and risk of disability progression [Calabresi PA et al. \u003Cem\u003ELancet Neurol\u003C\/em\u003E. 2014]. The present post hoc analysis assessed the effect of PEG-IFN-\u03b2-1a self-administered on a regular basis on the 2-year risk of disease progression in patients who had experienced a relapse in their MS.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EIn the first year of the study, patients (n = 1512) were randomized to subcutaneously self-injected PEG-IFN-\u03b2-1a 125 \u03bcg (n = 512) or placebo (n = 500) every 2 weeks or PEG-IFN-\u03b2-1a 125 \u03bcg every 4 weeks (n = 500). At 1 year, 1332 patients had completed the regimen (456 received placebo, and 876 received PEG-IFN-\u03b2-1a). These patients were re-randomized to self-inject the same dose of PEG-IFN-\u03b2-1a every 2 or 4 weeks. Thus, during year 2, each group contained 666 patients: 438 who continued to receive PEG-IFN-\u03b2-1a and 228 who newly received PEG-IFN-\u03b2-1a (delayed treatment). The baseline characteristics of the delayed arm (year 2) and the two arms from year 1 were comparable.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EAt 2 years, 143 patients had confirmed disability progression. The proportion of confirmed disability due to incomplete recovery from relapses among those who received PEG-IFN-\u03b2-1a every 2 weeks (10\/512, 2.0%) was significantly lower than in the delayed-treatment group (30\/500, 6.0%; \u003Cem\u003EP\u003C\/em\u003E = .0010). The proportion of confirmed disability due to incomplete recovery from relapses among those who received PEG-IFN-\u03b2-1a every 4 weeks (27\/500, 5.4%) was not significantly different from that of the delayed treatment group (30\/500, 6.0%; \u003Cem\u003EP\u003C\/em\u003E = .6824).\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EAt year 2, 138 of 1332 patients had confirmed disability progression. The rate of disability progression due to incomplete recovery from relapses was significantly lower in patients treated with PEG-IFN-\u03b2-1a every 2 weeks for both years (8\/438, 1.8%) compared with patients who received placebo in year 1 and who were now receiving PEG-IFN-\u03b2-1a every 4 weeks (16\/228, 7.0%; \u003Cem\u003EP\u003C\/em\u003E = .0006).\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EPEG-IFN-\u03b2-1a 125 \u03bcg administered every 2 weeks for 2 years lowered the risk of 24-week confirmed disability progression by 35% (\u003Cem\u003EP\u003C\/em\u003E \u0026lt; .05) compared with patients in whom therapy was delayed until year 2. In patients who had a relapse, this PEG-IFN-\u03b2-1a dose schedule significantly reduced (by 49%) the proportion of patients experiencing a relapse compared with those in the delayed group. About half of patients with confirmed disease progression experienced a relapse, supporting the view that disease progression cannot be fully explained by accumulated relapse-related disability.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EThe data support the idea that PEG-IFN-\u03b2-1a delivered at the optimal dose and timing may reduce the risk of relapse and improve recovery from relapse, both of which act to prevent further disease progression.\u003C\/p\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/29\/7.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzp7bp\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}